Devimistat

Devimistat

Clinical data
Other names	CPI-613
Legal status
Legal status	Investigational
Identifiers
IUPAC name 6,8-Bis(benzylsulfanyl)octanoic acid
CAS Number	95809-78-2
PubChem CID	24770514
DrugBank	12109
ChemSpider	28189062
UNII	E76113IR49
ChEMBL	ChEMBL3186849
CompTox Dashboard (EPA)	DTXSID70914807
ECHA InfoCard	100.231.125
Chemical and physical data
Formula	C22H28O2S2
Molar mass	388.58 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1=CC=C(C=C1)CSCCC(CCCCC(=O)O)SCC2=CC=CC=C2
InChI InChI=1S/C22H28O2S2/c23-22(24)14-8-7-13-21(26-18-20-11-5-2-6-12-20)15-16-25-17-19-9-3-1-4-10-19/h1-6,9-12,21H,7-8,13-18H2,(H,23,24) Key:ZYRLHJIMTROTBO-UHFFFAOYSA-N

Devimistat (INN; development code CPI-613) is an experimental anti-mitochondrial drug being developed by Cornerstone Pharmaceuticals. It is being studied for the treatment of patients with metastatic pancreatic cancer and relapsed or refractory acute myeloid leukemia (AML).

Devimistat's mechanism of action differs from other drugs, operating on the tricarboxylic acid cycle and inhibiting enzymes involved with cancer cell energy metabolism. A lipoic acid derivative different from standard cytotoxic chemotherapy, devimistat is currently being studied in combination with modified FOLFIRINOX to treat various solid tumors and heme malignancies.

Regulation

The U.S. Food and Drug Administration (FDA) has designated devimistat as an orphan drug for the treatment of pancreatic cancer, AML, myelodysplastic syndromes (MDS), peripheral T-cell lymphoma, and Burkitt's lymphoma, and given approval to initiate clinical trials in pancreatic cancer and AML.

Clinical trials

Clinical trials of the drug are underway including a Phase III open-label clinical trial to evaluate efficacy and safety of devimistat plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas.